{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T05:43:22Z","timestamp":1770702202507,"version":"3.49.0"},"reference-count":80,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,9]]},"DOI":"10.1097\/ppo.0000000000000065","type":"journal-article","created":{"date-parts":[[2014,10,9]],"date-time":"2014-10-09T10:46:54Z","timestamp":1412851614000},"page":"325-329","source":"Crossref","is-referenced-by-count":15,"title":["Opportunities for Targeting the Fatigue-Anorexia-Cachexia Symptom Cluster"],"prefix":"10.1097","volume":"20","author":[{"given":"Erin R.","family":"Alesi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Egidio","family":"del Fabbro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-6-20210203","first-page":"69","article-title":"Symptoms in the lives of terminal cancer patients: which is the most important Oncology.","volume":"71","author":"Kwon","year":"2006","journal-title":""},{"key":"R2-6-20210203","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1634\/theoncologist.5-5-353","article-title":"Impact of cancer-related fatigue on the lives of patients: new findings from the Fatigue Coalition.","volume":"5","author":"Curt","year":"2000","journal-title":"Oncologist"},{"key":"R3-6-20210203","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.jpainsymman.2011.03.007","article-title":"A Phase II dose titration study of thalidomide for cancer-associated anorexia.","volume":"43","author":"Davis","year":"2012","journal-title":"J Pain Symptom Manage"},{"key":"R4-6-20210203","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.1016\/S0140-6736(02)12022-8","article-title":"Dignity in the terminally ill: a cross-sectional, cohort study.","volume":"360","author":"Chochinov","year":"2002","journal-title":"Lancet"},{"key":"R5-6-20210203","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1007\/s00520-005-0899-z","article-title":"Symptom clustering in advanced cancer.","volume":"14","author":"Walsh","year":"2006","journal-title":"Support Care Cancer"},{"key":"R6-6-20210203","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1093\/jncimonographs\/lgm005","article-title":"Symptom burden: multiple symptoms and their impact as patient-reported outcomes.","volume":"37","author":"Cleeland","year":"2007","journal-title":"J Natl Cancer Inst Monogr"},{"key":"R7-6-20210203","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1007\/s00520-006-0038-5","article-title":"Symptom clusters: establishing the link between clinical practice and symptom management research.","volume":"14","author":"Miaskowski","year":"2006","journal-title":"Support Care Cancer"},{"key":"R8-6-20210203","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1586\/erp.12.41","article-title":"Symptom clusters in patients with metastatic cancer: a literature review.","volume":"12","author":"Thavarajah","year":"2012","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"R10-6-20210203","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1634\/theoncologist.2009-0153","article-title":"Randomized phase III clinical trial of five different arms of treatment in 332 patients with cancer cachexia.","volume":"15","author":"Mantovani","year":"2010","journal-title":"Oncologist"},{"key":"R11-6-20210203","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/S1470-2045(10)70218-7","article-title":"Definition and classification of cancer cachexia: an international consensus.","volume":"12","author":"Fearon","year":"2011","journal-title":"Lancet Oncol"},{"key":"R12-6-20210203","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1016\/j.jpainsymman.2010.02.006","article-title":"ASCPRO recommendations for the assessment of fatigue as an outcome in clinical trials.","volume":"39","author":"Barsevick","year":"2010","journal-title":"J Pain Symptom Manage"},{"key":"R13-6-20210203","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1615\/CritRevOncog.v17.i3.70","article-title":"The cachexia clinic: from staging to managing nutritional and functional problems in advanced cancer patients.","volume":"17","author":"Vigano","year":"2012","journal-title":"Crit Rev Oncog"},{"key":"R14-6-20210203","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1016\/j.cca.2011.12.008","article-title":"Integrative role of neuropeptides and cytokines in cancer anorexia-cachexia syndrome.","volume":"413","author":"Patra","year":"2012","journal-title":"Clin Chim Acta"},{"key":"R15-6-20210203","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1097\/00006842-200207000-00010","article-title":"Fatigue and proinflammatory cytokine activity in breast cancer survivors.","volume":"64","author":"Bower","year":"2002","journal-title":"Psychosom Med"},{"key":"R16-6-20210203","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1002\/hed.20607","article-title":"Changes in body mass, energy balance, physical function, and inflammatory state in patients with locally advanced head and neck cancer treated with concurrent chemoradiation after low-dose induction chemotherapy.","volume":"29","author":"Silver","year":"2007","journal-title":"Head Neck"},{"key":"R17-6-20210203","first-page":"197","article-title":"Association of serum IL-6 levels with comprehensive geriatric assessment variables in a population of elderly cancer patients.","volume":"11","author":"Mantovani","year":"2004","journal-title":"Oncol Rep"},{"key":"R18-6-20210203","doi-asserted-by":"crossref","first-page":"S630","DOI":"10.1097\/01.CCM.0000278529.44899.57","article-title":"Restoration of hormonal action and muscle protein.","volume":"35","author":"Ferrando","year":"2007","journal-title":"Crit Care Med"},{"key":"R19-6-20210203","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1038\/sj.npp.1300742","article-title":"Testosterone suppression of CRH-stimulated cortisol in men.","volume":"30","author":"Rubinow","year":"2005","journal-title":"Neuropsychopharmacology"},{"key":"R20-6-20210203","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1002\/1097-0142(19900915)66:6<1279::AID-CNCR2820660630>3.0.CO;2-R","article-title":"A controlled trial of megestrol acetate on appetite, caloric intake, nutritional status, and other symptoms in patients with advanced cancer.","volume":"66","author":"Bruera","year":"1990","journal-title":"Cancer"},{"key":"R21-6-20210203","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1200\/JCO.1993.11.4.762","article-title":"Phase III evaluation of four doses of megestrol acetate as therapy for patients with cancer anorexia andor cachexia.","volume":"11","author":"Loprinzi","year":"1993","journal-title":"J Clin Oncol"},{"key":"R22-6-20210203","first-page":"74","article-title":"Effectiveness of megestrol acetate in patients with advanced cancer: a randomized, double-blind, crossover study.","volume":"2","author":"Bruera","year":"1998","journal-title":"Cancer Prev Control"},{"key":"R23-6-20210203","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1200\/JCO.1996.14.4.1077","article-title":"Effects of medroxypro gesterone acetate on appetite, weight, and quality of life in advanced-stage nonhormone-sensitive cancer: a placebo-controlled multicenter study.","volume":"14","author":"Simons","year":"1996","journal-title":"J Clin Oncol"},{"key":"R24-6-20210203","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1016\/S0959-8049(98)00398-0","article-title":"Megestrol acetate in advanced, progressive, hormone-insensitive cancer. Effects on the quality of life: a placebo-controlled, randomised, multi-centre trial.","volume":"4","author":"Westman","year":"1999","journal-title":"Eur J Cancer"},{"issue":"2","key":"R25-6-20210203","first-page":"CD004310","article-title":"Megestrol acetate for the treatment of anorexia-cachexia syndrome.","author":"Berenstein","year":"2005","journal-title":"Cochrane Database Syst Rev"},{"key":"R27-6-20210203","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1089\/jpm.2006.9.409","article-title":"Symptom control in palliative carepart II: cachexiaanorexia and fatigue.","volume":"9","author":"del Fabbro","year":"2006","journal-title":"J Palliat Med"},{"key":"R28-6-20210203","doi-asserted-by":"crossref","first-page":"3076","DOI":"10.1200\/JCO.2012.44.4661","article-title":"Reduction of cancer-related fatigue with dexamethasone: a double-blind, randomized, placebo-controlled trial in patients with advanced cancer.","volume":"31","author":"Yennurajalingam","year":"2013","journal-title":"J Clin Oncol"},{"key":"R29-6-20210203","first-page":"751","article-title":"Action of oral methylprednisolone in terminal cancer patients: a prospective randomized double-blind study.","volume":"69","author":"Bruera","year":"1985","journal-title":"Cancer Treat Rep"},{"key":"R30-6-20210203","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1002\/1097-0142(197406)33:6<1607::AID-CNCR2820330620>3.0.CO;2-V","article-title":"Corticosteroid therapy of preterminal gastrointestinal cancer.","volume":"33","author":"Moertel","year":"1974","journal-title":"Cancer"},{"key":"R31-6-20210203","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1007\/s005200000218","article-title":"The use of corticosteroids in home palliative care.","volume":"9","author":"Mercadante","year":"2001","journal-title":"Support Care Cancer"},{"key":"R32-6-20210203","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1007\/s00520-003-0488-y","article-title":"Randomized study of dexamethasone treatment for delayed emesis, anorexia and fatigue induced by irinotecan.","volume":"11","author":"Inoue","year":"2003","journal-title":"Support Care Cancer"},{"key":"R33-6-20210203","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1136\/pgmj.59.697.702","article-title":"Corticosteroids in terminal cancera prospective analysis of current practice.","volume":"59","author":"Hanks","year":"1983","journal-title":"Postgrad Med J"},{"key":"R34-6-20210203","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1136\/bmj.305.6860.969","article-title":"Corticosteroids in advanced cancer.","volume":"305","author":"Twycross","year":"1992","journal-title":"BMJ"},{"key":"R35-6-20210203","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1016\/j.jpainsymman.2009.09.021","article-title":"Associations among hypogonadism, C-reactive protein, symptom burden, and survival in male cancer patients with cachexia: a preliminary report.","volume":"39","author":"del Fabbro","year":"2010","journal-title":"J Pain Symptom Manage"},{"key":"R36-6-20210203","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/S0885-3924(03)00331-2","article-title":"Hypogonadism and sexual dysfunction in male cancer survivors receiving chronic opioid therapy.","volume":"26","author":"Rajagopal","year":"2003","journal-title":"J Pain Symptom Manage"},{"key":"R37-6-20210203","doi-asserted-by":"crossref","first-page":"3476","DOI":"10.1210\/jc.2006-2744","article-title":"Prevalence and consequences of androgen deficiency in young male cancer survivors in a controlled cross-sectional study.","volume":"92","author":"Greenfield","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"R38-6-20210203","doi-asserted-by":"crossref","first-page":"2949","DOI":"10.1002\/cncr.22339","article-title":"The impact of hypogonadism and autonomic dysfunction on fatigue, emotional function, and sexual desire in male patients with advanced cancer: a pilot study.","volume":"107","author":"Strasser","year":"2006","journal-title":"Cancer"},{"key":"R39-6-20210203","first-page":"2495","article-title":"Hypogonadism in male patients with metastatic cancer prior to chemotherapy.","volume":"42","author":"Chlebowski","year":"1982","journal-title":"Cancer Res"},{"key":"R40-6-20210203","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1001\/jama.283.6.763","article-title":"Testosterone replacement and resistance exercise in HIV-infected men with weight loss and low testosterone levels.","volume":"283","author":"Bhasin","year":"2000","journal-title":"JAMA"},{"key":"R41-6-20210203","doi-asserted-by":"crossref","first-page":"2599","DOI":"10.1007\/s00520-013-1832-5","article-title":"Testosterone replacement for fatigue in hypogonadal ambulatory males with advanced cancer: a preliminary double-blind placebo-controlled trial.","volume":"21","author":"del Fabbro","year":"2013","journal-title":"Support Care Cancer"},{"key":"R42-6-20210203","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/S1470-2045(13)70055-X","article-title":"Effects of enobosarm on muscle wasting and physical function in patients with cancer: a double-blind, randomised controlled phase 2 trial.","volume":"14","author":"Dobs","year":"2013","journal-title":"Lancet Oncol"},{"key":"R43-6-20210203","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1038\/35086018","article-title":"Ghrelin: an orexigenic and somatotrophic signal from the stomach.","volume":"2","author":"Inui","year":"2001","journal-title":"Nat Rev Neurosci"},{"key":"R44-6-20210203","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1002\/cncr.24917","article-title":"Effects by daily long term provision of ghrelin to unselected weight-losing cancer patients: a randomized double-blind study.","volume":"116","author":"Lundholm","year":"2010","journal-title":"Cancer"},{"key":"R45-6-20210203","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s00520-012-1500-1","article-title":"Therapeutic potential of anamorelin, a novel, oral ghrelin mimetic, in patients with cancer-related cachexia: a multicenter, randomized, double-blind, crossover, pilot study.","volume":"21","author":"Garcia","year":"2013","journal-title":"Support Care Cancer"},{"key":"R46-6-20210203","first-page":"suppl","article-title":"A phase II randomized, placebo-controlled, double-blind study of the efficacy and safety of RC-1291 (RC) for the treatment of cancer cachexia.","volume":"2518","author":"Garcia","year":"2007","journal-title":"J Clin Oncol (Meeting Abstracts)"},{"key":"R47-6-20210203","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.ghir.2008.12.003","article-title":"Pharmacodynamic hormonal effects of anamorelin, a novel oral ghrelin mimetic and growth hormone secretagogue in healthy volunteers.","volume":"19","author":"Garcia","year":"2009","journal-title":"Growth Horm IGF Res"},{"key":"R48-6-20210203","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/s13539-011-0035-5","article-title":"The role of myostatin in muscle wasting: an overview.","volume":"2","author":"Elkina","year":"2011","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"R49-6-20210203","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1097\/SPC.0000000000000013","article-title":"Myostatin inhibitors as therapies for muscle wasting associated with cancer and other disorders.","volume":"7","author":"Smith","year":"2013","journal-title":"Curr Opin Support Palliat Care"},{"key":"R50-6-20210203","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.cell.2010.07.011","article-title":"Reversal of cancer cachexia and muscle wasting by ActRIIB antagonism leads to prolonged survival.","volume":"142","author":"Zhou","year":"2010","journal-title":"Cell"},{"key":"R51-6-20210203","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1634\/theoncologist.2010-0019","article-title":"More is better: a multimodality approach to cancer cachexia.","volume":"15","author":"del Fabbro","year":"2010","journal-title":"Oncologist"},{"key":"R52-6-20210203","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/j.ejca.2008.02.033","article-title":"Cancer cachexia: developing multimodal therapy for a multidimensional problem.","volume":"44","author":"Fearon","year":"2008","journal-title":"Eur J Cancer"},{"key":"R53-6-20210203","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.clnu.2006.10.005","article-title":"Cancer wasting and quality of life react to early individualized nutritional counselling.","volume":"26","author":"Ravasco","year":"2007","journal-title":"Clin Nutr"},{"key":"R54-6-20210203","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1089\/jpm.2011.0098","article-title":"Clinical outcomes and contributors to weight loss in a cancer cachexia clinic.","volume":"14","author":"del Fabbro","year":"2011","journal-title":"J Palliat Med"},{"key":"R55-6-20210203","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1080\/01635580701365068","article-title":"Effects of eicosapentaenoic and docosahexaenoic n-3 fatty acids from fish oil and preferential Cox-2 inhibition on systemic syndromes in patients with advanced lung cancer.","volume":"59-","author":"Cerchietti","year":"2007","journal-title":"Nutr Cancer"},{"key":"R56-6-20210203","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1158\/1055-9965.EPI-05-0538","article-title":"A phase II study with antioxidants, both in the diet and supplemented, pharmaconutritional support, progestagen, and anti-cyclooxygenase-2 showing efficacy and safety in patients with cancer-related anorexiacachexia and oxidative stress.","volume":"15","author":"Mantovani","year":"2006","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"R57-6-20210203","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1038\/sj.bjc.6690654","article-title":"The effect of an oral nutritional supplement enriched with fish oil on weight-loss in patients with pancreatic cancer.","volume":"81","author":"Barber","year":"1999","journal-title":"Br J Cancer"},{"key":"R58-6-20210203","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1038\/sj.bjc.6601620","article-title":"Reduced total energy expenditure and physical activity in cachectic patients with pancreatic cancer can be modulated by an energy and protein dense oral supplement enriched with n-3 fatty acids.","volume":"90","author":"Moses","year":"2004","journal-title":"Br J Cancer"},{"key":"R59-6-20210203","doi-asserted-by":"crossref","first-page":"3401","DOI":"10.1200\/JCO.2005.04.5724","article-title":"Double-blind, placebo-controlled, randomized study of eicosapentaenoic acid diester in patients with cancer cachexia.","volume":"24","author":"Fearon","year":"2006","journal-title":"J Clin Oncol"},{"key":"R60-6-20210203","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1200\/JCO.2003.01.101","article-title":"Effect of fish oil on appetite and other symptoms in patients with advanced cancer and anorexiacachexia: a double-blind, placebo-controlled study.","volume":"21","author":"Bruera","year":"2003","journal-title":"J Clin Oncol"},{"key":"R61-6-20210203","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1002\/cncr.20362","article-title":"Phase II study of high-dose fish oil capsules for patients with cancer-related cachexia.","volume":"101","author":"Burns","year":"2004","journal-title":"Cancer"},{"key":"R62-6-20210203","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1207\/S15327914NC3602_6","article-title":"Effect of oral eicosapentaenoic acid on weight loss in patients with pancreatic cancer.","volume":"36","author":"Wigmore","year":"2000","journal-title":"Nutr Cancer"},{"key":"R63-6-20210203","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1136\/gut.52.10.1479","article-title":"Effect of a protein and energy dense n-3 fatty acid enriched oral supplement on loss of weight and lean tissue in cancer cachexia: a randomized double blind trial.","volume":"52","author":"Fearon","year":"2003","journal-title":"Gut"},{"key":"R65-6-20210203","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1002\/cncr.25709","article-title":"Nutritional intervention with fish oil provides a benefit over standard of care for weight and skeletal muscle mass in patients with nonsmall cell lung cancer receiving chemotherapy.","volume":"117","author":"Murphy","year":"2011","journal-title":"Cancer"},{"key":"R66-6-20210203","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1093\/jnci\/djt181","article-title":"Wisconsin ginseng (Panax quinquefolius) to improve cancer-related fatigue: a randomized, double-blind trial, N07C2.","volume":"105","author":"Barton","year":"2013","journal-title":"J Natl Cancer Inst"},{"key":"R67-6-20210203","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1023\/A:1008329821941","article-title":"Thalidomide in patients with cachexia due to terminal cancer: preliminary report.","volume":"10","author":"Bruera","year":"1999","journal-title":"Ann Oncol"},{"key":"R68-6-20210203","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1046\/j.1365-2036.2003.01457.x","article-title":"Oesophageal cancer and cachexia: the effect of short-term treatment with thalidomide on weight loss and lean body mass.","volume":"17","author":"Khan","year":"2003","journal-title":"Ailment Pharmacol Ther"},{"key":"R69-6-20210203","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1136\/gut.2004.047563","article-title":"Thalidomide in the treatment of cancer cachexia: a randomized placebo controlled trial.","volume":"54","author":"Gordon","year":"2005","journal-title":"Gut"},{"key":"R70-6-20210203","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.jpainsymman.2011.03.007","article-title":"A phase II dose titration study of thalidomide for cancer-associated anorexia.","volume":"43","author":"Davis","year":"2012","journal-title":"J Pain Symptom Manage"},{"key":"R71-6-20210203","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1111\/j.1365-2354.2011.01255.x","article-title":"Poor tolerability of thalidomide in end-stage oesophageal cancer.","volume":"20","author":"Wilkes","year":"2011","journal-title":"Eur J Cancer Care"},{"key":"R73-6-20210203","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1177\/082585979401000105","article-title":"A phase II study of delta-9-tetrahydrocannabinol for appetite stimulation in cancer-associated anorexia.","volume":"10","author":"Nelson","year":"1994","journal-title":"J Palliat Care"},{"key":"R74-6-20210203","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/0091-3057(91)90385-F","article-title":"Recent clinical experience with dronabinol.","volume":"40","author":"Plasse","year":"1991","journal-title":"Pharmacol Biochem Behav"},{"key":"R75-6-20210203","doi-asserted-by":"crossref","first-page":"3394","DOI":"10.1200\/JCO.2005.05.1847","article-title":"Comparison of orally administered cannabis extract and delta-9-tetrahydrocannabinol in treating patients with cancer-related anorexia-cachexia syndrome: a multi-center, phase III, randomized,double-blind, placebo-controlled clinical trial from the Cannabis-in-Cachexia-Study-Group.","volume":"24","author":"Strasser","year":"2006","journal-title":"J Clin Oncol"},{"key":"R76-6-20210203","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1200\/JCO.2005.02.8506","article-title":"Patient-controlled methylphenidate for cancer fatigue: a double-blind, randomized, placebo-controlled trial.","volume":"24","author":"Bruera","year":"2006","journal-title":"J Clin Oncol"},{"key":"R77-6-20210203","doi-asserted-by":"crossref","first-page":"3673","DOI":"10.1200\/JCO.2010.28.1444","article-title":"Phase III, randomized, double-blind, placebo-controlled study of long-acting methylphenidate for cancer-related fatigue: North Central Cancer Treatment Group NCCTG-N05C7 trial.","volume":"28","author":"Moraska","year":"2010","journal-title":"J Clin Oncol"},{"key":"R78-6-20210203","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/j.jpainsymman.2009.03.011","article-title":"Efficacy of dexmethylphenidate for the treatment of fatigue after cancer chemotherapy: a randomized clinical trial.","volume":"38","author":"Lower","year":"2009","journal-title":"J Pain Symptom Manage"},{"key":"R79-6-20210203","doi-asserted-by":"crossref","first-page":"5102","DOI":"10.1002\/cncr.25424","article-title":"Methylphenidate for fatigue in ambulatory men with prostate cancer.","volume":"116","author":"Roth","year":"2010","journal-title":"Cancer"},{"key":"R80-6-20210203","doi-asserted-by":"crossref","first-page":"2421","DOI":"10.1200\/JCO.2012.45.3696","article-title":"Methylphenidate andor a nursing telephone intervention for fatigue in patients with advanced cancer, a randomized, placebo-controlled, phase II trial.","volume":"31","author":"Bruera","year":"2013","journal-title":"J Clin Oncol"},{"key":"R81-6-20210203","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1097\/PPO.0000000000000018","article-title":"A randomized, double-blind, 2-period, placebo-controlled crossover trial of a sustained-release methylphenidate in the treatment of fatigue in cancer patients.","volume":"20","author":"Escalante","year":"2014","journal-title":"Cancer J"},{"issue":"11","key":"R83-6-20210203","first-page":"CD006788","article-title":"Pharmacologic treatments for fatigue associated with palliative care.","author":"Peuckmann","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"key":"R84-6-20210203","doi-asserted-by":"crossref","first-page":"e84391","DOI":"10.1371\/journal.pone.0084391","article-title":"Effect of methylphenidate in patients with cancer-related fatigue: a systematic review and meta-analysis.","volume":"9","author":"Gong","year":"2014","journal-title":"PLoS One"},{"key":"R85-6-20210203","first-page":"1012","article-title":"Central tenet of cancer cachexia therapy: do patients with advanced cancer have exploitable anabolic potential Am J Clin Nutr.","volume":"98","author":"Prado","year":"2013","journal-title":""}],"container-title":["The Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/PPO.0000000000000065","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T05:21:02Z","timestamp":1620969662000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00130404-201409000-00006"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,9]]},"references-count":80,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2014]]}},"URL":"https:\/\/doi.org\/10.1097\/ppo.0000000000000065","relation":{},"ISSN":["1528-9117"],"issn-type":[{"value":"1528-9117","type":"print"}],"subject":[],"published":{"date-parts":[[2014,9]]}}}